Moore Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Moore Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,104	Closed	-$1.87M	–	673
2025 Q3	$1.87M	Buy	+4,104	New	+$1.67M	0.03%	370
2024 Q1	–	Sell	-4,635	Closed	-$887K	–	440
2023 Q4	$887K	Sell	4,635 -17,350	-79%	-$2.96M	0.02%	284
2023 Q3	$3.89M	Buy	+21,985	New	+$4.19M	0.07%	192
2023 Q1	–	Sell	-10,000	Closed	-$2.38M	–	490
2022 Q4	$2.38M	Sell	10,000 -11,247	-53%	-$2.4M	0.06%	252
2022 Q3	$4.25M	Buy	+21,247	New	+$4.05M	0.1%	225
2015 Q2	–	Sell	-5,500	Closed	-$574K	–	412
2015 Q1	$574K	Buy	+5,500	New	+$557K	0.01%	380

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Moore Capital Management's ALNY Position: Q4 2025 in Review

Moore Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 4,104 shares — an estimated $1.87M sold.

Moore Capital Management first reported a position in ALNY in Q1 2015 and held it in 6 quarters. The position peaked at $4.25M in Q3 2022. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Moore Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Moore Capital Management sold 4,104 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $1.87M.
Moore Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2015 and held it in 6 quarters.
Moore Capital Management's Alnylam Pharmaceuticals position peaked at $4.25M in Q3 2022.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Moore Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.